United States of America v. Humana Inc

District Court, W.D. Kentucky·Decided March 30, 2021·No. 3:18-cv-00061·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF KENTUCKY LOUISVILLE DIVISION CIVIL ACTION NO. 3:18-CV-61-GNS-CHL

UNITED STATES OF AMERICA, ex rel. STEVEN SCOTT, Plaintiff,

v.

HUMANA INC., Defendant.

MEMORANDUM OPINION AND ORDER

Before the Court is a motion for in camera review (DN 286) filed by Relator Steven Scott (“Relator”). Defendant Humana Inc. (“Humana”) filed a response (DN 297) to which Relator filed a reply (DN 303). Therefore, the motion is ripe for review. I. BACKGROUND In March 2018, Relator served Rule 45 subpoenas on three non-parties: (1) Milliman, Inc. (“Milliman”), Humana’s certifying actuary; (2) Walmart Inc. (“Walmart”), a preferred pharmacy in the Walmart Plan; and (3) The Walgreens Company (“Walgreens”), another preferred pharmacy in the Walmart Plan. (DN 286, at PageID # 22920.) Relator states that Humana admitted that it communicated with these non-parties concerning their responses to Relator’s Rule 45 subpoenas and that it reviewed Milliman’s production before it was made to Relator. (Id., at PageID #22918; DN 286-2.) Relator states that he has concerns that Humana may have improperly communicated to non-parties regarding their responses to Relator’s Rule 45 subpoenas. (Id., at PageID # 22918.) Relator served a request for production on July 30, 2018 requesting “[a]ll Communications between You (including Your attorneys) and any non-party that has been subpoenaed in this action relating to any subpoena served in this action, including without limitation Communications between You (including Your attorneys) and CMS, Walmart, Walgreens, and Milliman relating to any subpoenas served in this action.” (DN 137-3, at PageID # 1805.) On September 30, 2018, Humana produced responses reflecting that it sent 188 emails and attachments regarding Relator’s subpoenas, and on October 8, 2018, Humana produced a privilege log for the production. (DN 286, at PageID # 22921.) After motions practice in DN 137, 145, and 147 concerning these same subpoenaed documents, the Court granted Relator’s

motion to compel Humana to supplement its privilege log. (DN 223.) Humana served its supplemental privilege log on October 4, 2019. (DN 286, at PageID # 22922.) On October 16, 2019, Relator informed Humana that he believed that numerous documents on the supplemental privilege log had been improperly withheld. (Id., at PageID # 22922.) On January 27, 2020 Humana produced a second supplemental privilege log. (DN 286- 11.) On February 17, 2020, Relator provided a list of approximately 125 documents that he believes do not indicate any possible source of privilege, and Relator subsequently narrowed the list down to thirty-five documents using a random number generator which are now the subject of the instant motion. (DN 286, at PageID # 22925) On September 25, 2020, the Court granted

in part Relator’s motion for in camera review, but reserved any ruling on the applicability of the privilege and whether the documents at issue should be produced as requested by Relator pending completion of the in camera review. (DN 384.) The Court now addresses those issues. Relator argues that within the thirty-five documents there are five documents that cannot be privileged because they consist of presentations and memoranda created before the Rule 45 subpoenas were issued. (DN 286, at PageID # 22925.) Relator further argues that the common interest privilege does not shield any of the documents at issue because Humana and the subpoenaed nonparties share a common business relationship, but do not share any common legal interest required for the privilege to attach. (DN 286, at PageID # 22928-32.) Humana argues that Relator fails to show any facts indicating that Humana’s assertions of privilege are invalid or subject to exception. (DN 297, at PageID # 23203.) Humana further argues that Relator has failed to articulate why the communications at issue are relevant to the claims of this case since nothing that Humana’s lawyers communicated after this litigation commenced is likely to produce admissible evidence regarding Relator’s allegations of False Claims Act

violations. (DN 297, at PageID # 23203.) II. LEGAL STANDARD Rule 26(b) of the Federal Rules of Civil Procedure governs the scope of discovery. Rule 26(b)(1) provides that “[p]arties may obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case . . .” Fed. R. Civ. P. 26(b)(1). This language is broadly construed by the federal courts to include “any matter that bears on, or that reasonably could lead to other matter[s] that could bear on, any issue that is or may be in the case.” Oppenheimer Fund, Inc. v. Sanders, 437 U.S. 340, 351 (1978). “When faced with questions over, or disputes about, what information or documents may be obtained based on

their relevancy, it is axiomatic that the trial court is afforded broad discretion to determine the boundaries of inquiry.” Janko Enters. v. Long John Silver’s, Inc., No. 3:12-cv-345-S, 2013 WL 5308802, at *2 (W.D. Ky. Aug. 19, 2013) (citing Chrysler v. Fedders Corp., 643 F.2d 1229, 1240 (6th Cir. 1981)). In its September 25, 2020 order, the Court found that the documents at issue are relevant for discovery purposes. (DN 384, at PageID # 43076.) Accordingly, the Court sets forth below the standards for determining whether Humana’s privilege claims are valid. a. Work Product Doctrine The work product doctrine, or “work product privilege” as it is sometimes known, was first recognized by the United States Supreme Court in Hickman v. Taylor, 329 U.S. 495, 67 S.Ct. 385, 91 L.Ed. 451 (1947). While the work product doctrine has some conceptual overlap with the attorney-client privilege, it “is distinct from and broader than the attorney-client privilege.” United States v. Nobles, 422 U.S. 225, 238, 95 S.Ct. 2160, 45 L.Ed.2d 141 (1975); In re Antitrust Grand Jury, 805 F.2d at 163. The attorney-client privilege operates to protect only confidential communications between an attorney and a client, while the work product doctrine exists to protect

any document prepared by or for an attorney in anticipation of litigation. In re Antitrust Grand Jury, 805 F.2d at 163 (citing In re Special September 1978 Grand Jury, 640 F.2d 49, 62 (7th Cir.1980)). Federal courts apply the federal work product doctrine. In re Powerhouse Licensing, LLC, 441 F.3d 467, 473 (6th Cir. 2006). The doctrine is currently incorporated in Fed. R. Civ. P. 26(b)(3) to protect from discovery those documents or tangible things prepared in anticipation of litigation by or for a party or the party’s representative absent a showing by the party seeking production of substantial need and the unavailability of such information from another source. Id. Rule 26(b)(3) protects: (1) a document or tangible thing; (2) prepared in anticipation of

litigation or for trial; (3) by or for a party or its representative. In re Professionals Direct Ins. Co., 578 F.3d 432, 438 (6th Cir. 2009).

Free access — add to your briefcase to read the full text and ask questions with AI

United States of America v. Humana Inc, (W.D. Ky. 2021).

United States of America v. Humana Inc (United States of America v. Humana Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Hickman v. Taylor
329 U.S. 495 (Supreme Court, 1947)
United States v. Nobles
422 U.S. 225 (Supreme Court, 1975)
Oppenheimer Fund, Inc. v. Sanders
437 U.S. 340 (Supreme Court, 1978)
In Re Professionals Direct Insurance
578 F.3d 432 (Sixth Circuit, 2009)
In Re Powerhouse Licensing, LLC
441 F.3d 467 (Sixth Circuit, 2006)
Libbey Glass, Inc. v. Oneida
197 F.R.D. 342 (N.D. Ohio, 1999)
United States v. Bergonzi
216 F.R.D. 487 (N.D. California, 2003)
Broessel v. Triad Guaranty Insurance
238 F.R.D. 215 (W.D. Kentucky, 2006)